Achim Schneeberger

Summary

Publications

  1. ncbi request reprint Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing
    A Schneeberger
    AFFiRiS, Viehmarktgasse 2A, A 1030 Vienna, Austria
    J Nutr Health Aging 13:264-7. 2009
  2. ncbi request reprint AFFITOME® technology in neurodegenerative diseases: the doubling advantage
    Achim Schneeberger
    AFFiRiS AG, Vienna, Austria
    Hum Vaccin 6:948-52. 2010
  3. doi request reprint Vaccination for Parkinson's disease
    A Schneeberger
    AFFiRiS AG, Karl Farkas Gasse 22, A 1030 Vienna, Austria
    Parkinsonism Relat Disord 18:S11-3. 2012
  4. pmc Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines
    Markus Mandler
    AFFiRiS AG, Karl Farkas Gasse 22, A 1030, Vienna, Austria
    PLoS ONE 10:e0115237. 2015

Collaborators

  • Markus Mandler
  • Yeliz Cinar
  • Petra Gruber
  • Radmila Santic
  • Walter Schmidt
  • Susanne Aileen Funke
  • Dagmar Pichler
  • Dieter Willbold
  • Frank Mattner

Detail Information

Publications4

  1. ncbi request reprint Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing
    A Schneeberger
    AFFiRiS, Viehmarktgasse 2A, A 1030 Vienna, Austria
    J Nutr Health Aging 13:264-7. 2009
    ..Further clinical testing will focus on the identification of the optimal vaccine dose and immunization schedule. Together, result of these trials will provide a solid basis for clinical POC studies...
  2. ncbi request reprint AFFITOME® technology in neurodegenerative diseases: the doubling advantage
    Achim Schneeberger
    AFFiRiS AG, Vienna, Austria
    Hum Vaccin 6:948-52. 2010
    ....
  3. doi request reprint Vaccination for Parkinson's disease
    A Schneeberger
    AFFiRiS AG, Karl Farkas Gasse 22, A 1030 Vienna, Austria
    Parkinsonism Relat Disord 18:S11-3. 2012
    ..PD01, the first in class aSyn vaccine developed by AFFiRiS is about to enter the clinical phase of development...
  4. pmc Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines
    Markus Mandler
    AFFiRiS AG, Karl Farkas Gasse 22, A 1030, Vienna, Austria
    PLoS ONE 10:e0115237. 2015
    ..Thus, the AFFITOME-technology delivers vaccines capable of inducing a distinct Ab response. Their features may be beneficial to AD-patients, a hypothesis currently tested within a phase-II-study. ..